January 4 | 2024
2cureX announces changes to the Board of Directors.
Read more
December 29 | 2023
2cureX announces changes to the management
Read more
November 23 | 2023
2cureX publishes interim report for the third quarter of 2023
Read more
November 14 | 2023
KOMMUNIKÉ FRÅN EXTRA BOLAGSSTÄMMAN I 2CUREX AB (PUBL)
Read more
November 14 | 2023
BULLETIN FROM THE EXTRAORDINARY GENERAL MEETING IN 2CUREX AB (PUBL)
Read more
October 26 | 2023
Strategy update: Leapfrogging to the decentralization of IndiTreat® testing through full focus on automation
Read more
October 25 | 2023
KALLELSE TILL EXTRA BOLAGSSTÄMMA I 2CUREX AB (PUBL)
Read more
October 25 | 2023
NOTICE TO ATTEND THE EXTRAORDINARY GENERAL MEETING OF 2CUREX AB (PUBL)
Read more
August 24 | 2023
2cureX publishes interim report for Q2 2023
Read more
May 25 | 2023
Kommuniké från årsstämma i 2cureX AB
Read more
May 25 | 2023
2cureX publishes interim report for the first quarter of 2023
Read more
April 27 | 2023
Kallelse till årsstämma i 2cureX AB (publ)
Read more
April 27 | 2023
Notice of annual general meeting of 2cureX AB (publ)
Read more
April 25 | 2023
2cureX’s CEO Fernando Andreu purchases shares in the company
Read more
April 20 | 2023
2cureX offentliggör årsredovisning för räkenskapsåret 2022
Read more
April 20 | 2023
2cureX publishes the annual report for the fiscal year 2022
Read more
April 12 | 2023
2cureX has received a grant from the Innovation Fund Denmark to support clinical development of a novel IndiTreat® product.
Read more
April 6 | 2023
2cureX strengthens its IndiTreat® automation project with a prestigious grant from the German Federal Ministry of Education and Research
Read more